» Articles » PMID: 26681237

Predictors of Psychotropic Medication Adherence Among HIV+ Individuals Living with Bipolar Disorder

Overview
Publisher Sage Publications
Specialty Psychiatry
Date 2015 Dec 19
PMID 26681237
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: HIV infection and bipolar disorder are highly comorbid and associated with frontostriatal disruption, emotional dysregulation, and neurocognitive impairment. Psychiatric and cognitive factors have been linked to antiretroviral nonadherence; however, predictors of psychotropic adherence among HIV+ individuals with psychiatric comorbidities have not been explored. We evaluated predictors of psychotropic adherence among individuals with HIV infection and bipolar disorder.

Method: Psychiatric medication adherence of 50 participants with HIV infection and bipolar disorder was tracked for 30 days using Medication Event Monitoring Systems. Participants completed neurocognitive, neuromedical, and psychiatric batteries.

Results: Mean psychotropic adherence rate was 78%; 56% of participants achieved ≥90% adherence. Younger age and onset of depressive symptoms, more severe current depressive symptoms, number of previous psychiatric hospitalizations and suicide attempts, poorer neurocognition, and more negative attitudes and self-beliefs toward medications univariably predicted worse psychotropic adherence (p's < .10). A multivariable model demonstrated a combination of current depressive symptoms and more negative attitudes toward medications significantly predicting poorer adherence (R(2 )= 0.27, p < 0.003). Secondary analyses revealed an interaction between neurocognition and mood, such that individuals with HIV infection and bipolar disorder who had greater executive dysfunction and depressive symptoms evidenced the poorest psychotropic adherence (p < 0.001).

Conclusions: Both psychiatric and neurocognitive factors contribute to poorer psychotropic adherence among HIV+ individuals with serious mental illness. Adherence interventions aimed at remediating these factors may be especially fruitful.

Citing Articles

Barriers and facilitators to maintaining a high level of polypharmacy adherence in people living with HIV: A scoping review.

He J, Zhu Z, Sun M, Liu X, Yu J, Zhang L Front Pharmacol. 2023; 14:1013688.

PMID: 36937849 PMC: 10017548. DOI: 10.3389/fphar.2023.1013688.


A randomized controlled trial of customized adherence enhancement (CAE-E): study protocol for a hybrid effectiveness-implementation project.

Levin J, Briggs F, Blixen C, Bauer M, Einstadter D, Albert J Trials. 2022; 23(1):634.

PMID: 35927740 PMC: 9351150. DOI: 10.1186/s13063-022-06517-0.


Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis.

Foley L, Larkin J, Lombard-Vance R, Murphy A, Hynes L, Galvin E BMJ Open. 2021; 11(9):e044987.

PMID: 34475141 PMC: 8413882. DOI: 10.1136/bmjopen-2020-044987.


The Relationship Between Medication Attitudes and Medication Adherence Behavior in Adults With Bipolar Disorder.

Levin J, Aebi M, Howland M, Barboza M, Eskew L, Tatsuoka C J Nerv Ment Dis. 2020; 208(2):87-93.

PMID: 31929465 PMC: 7316161. DOI: 10.1097/NMD.0000000000001083.


Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Levin J, Krivenko A, Howland M, Schlachet R, Sajatovic M CNS Drugs. 2016; 30(9):819-35.

PMID: 27435356 DOI: 10.1007/s40263-016-0368-x.


References
1.
Beyer J, Kuchibhatla M, Gersing K, Krishnan K . Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology. 2004; 30(2):401-4. DOI: 10.1038/sj.npp.1300608. View

2.
McDonald-Miszczak L, Maris P, Fitzgibbon T, Ritchie G . A pilot study examining older adults' beliefs related to medication adherence: the BERMA survey. J Aging Health. 2004; 16(5):591-614. DOI: 10.1177/0898264304265772. View

3.
Fleck D, Keck Jr P, Corey K, Strakowski S . Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry. 2005; 66(5):646-52. DOI: 10.4088/jcp.v66n0517. View

4.
Hinkin C, Barclay T, Castellon S, Levine A, Durvasula R, Marion S . Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2006; 11(2):185-94. PMC: 2867605. DOI: 10.1007/s10461-006-9152-0. View

5.
Cruess D, Kalichman S, Amaral C, Swetzes C, Cherry C, Kalichman M . Benefits of adherence to psychotropic medications on depressive symptoms and antiretroviral medication adherence among men and women living with HIV/AIDS. Ann Behav Med. 2011; 43(2):189-97. PMC: 4285379. DOI: 10.1007/s12160-011-9322-9. View